antibody drug conjugates

News

MSD, Daiichi Sankyo lung cancer ADC starts phase 3

One of three antibody-drug conjugates licensed by MSD for $4 billion upfront last year has started phase 3 testing in a form of lung cancer.

News

Ipsen forges another ADC alliance, this time with Foreseen

Ipsen’s big partnering push to expand its pipeline shows no signs of abating, with the latest deal a $1 billion wager on an antibody-drug conjugate (ADC) for cancer developed by Foreseen Bi

News

BMS hands back rights to cancer ADC licensed from Eisai

Bristol-Myers Squibb has ended a $3.1 billion strategic collaboration with Eisai focusing on antibody-drug conjugates (ADCs) and returned rights to the lead drug in the alliance.

Oncology

The ‘elegant science’ in achieving the promise of ADCs

In this week’s episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Raquel Izumi, chief operating officer and co-founder of Vincerx Pharma, who is on a mission to impr

Oncology